Skip to main content
. 2015 Oct;100(10):1327–1333. doi: 10.3324/haematol.2014.117077

Figure 2.

Figure 2.

Kaplan-Meier curves of progression-free survival by cytogenetic risk groups for patients treated with (A) POM + LoDEX and (B) HiDEX. aLog-rank P vs. standard risk. HiDEX: high-dose dexamethasone; HR: hazard ratio; LoDEX: low-dose dexamethasone; PFS: progression-free survival; POM: pomalidomide.